Associate Scientist II, RNAi Discovery

Overview

The research and development-based transcriptomics team is seeking motivated and reliable Research Associate Scientist II. The focus will be on performing gene expression experiments to support lead drug candidates screening, target and biomarker discovery, and translational research. The position is heavily experimental and requires a passion for lab work, data generation, and assays optimization. 

This position is onsite and will be primarily located in Cambridge, MA.  

Key Responsibilities

• Execute day to day operations for bulk RNASeq sample preparation, including RNA isolation, library preparation, QC and sequencing.
• Responsible for the operation and maintenance of NGS equipment and supplies
• Maintain samples and oversee logistics of data generation and collection. Work with the bioinformatics group to streamline and improve data collection and analytical processes.
• Prepare protocols and data reports
• Troubleshoot technical problems and participate in the continuing development and optimization of existing and new protocols and technologies
• Assist additional personnel / projects as needed
• Adaptwell to the changing platform needs, in workflow, projects and other tasks as required by the platform.

Qualifications

• A BS in a biological science with at least 2 years of hands-on laboratory experience in molecular /cell biology are required 
• Experience with NGS methods   is desired, including Illumina, ONT, single cell and spatial platforms
• Experienced with laboratory automation such as Beckman i7 or other systems will be a plus
• Intense orientation to details orientation, accuracy, reliability and precision when executing experiments in the laboratory. 
• Ability to manage multiple projects simultaneously, desire to drive innovation, and willingness to learn.
• Team player, strong motivation and commitment, proactive mindset, getting things done attitude. 
  
  

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.